Back to Blog

Wholesale Distributor Annual Reporting Deadline

Christian Souza

This Annual Reporting is a must!

The Annual Reporting by Prescription Drug Wholesale Distributors and 4 Third-Party Logistics Providers deadline will be on March 31st 2015. This means that if you are pharmaceutical wholesaler you must submit your company information to the FDA. The actual FDA guidance:

This guidance describes FDA’s expectations for prescription drug wholesale distributors (wholesale distributors) and third-party logistics providers (3PLs) for the annual reporting to FDA as required under the Drug Supply Chain Security Act of 2013 (DSCSA). Under section 584(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360eee-3(b)), beginning November 27, 2014, 3PLs must report certain information to FDA, including State licensure information for each facility and the name and address for each facility. Under section 503(e)(2)(A) (21 U.S.C. 353(e)(2)(A) (as amended by the DSCSA), beginning January 1, 2015, wholesale distributors also must report certain information to FDA, including State licensure information for each facility, contact information for each facility, and any significant disciplinary actions taken by a State or the Federal Government. This guidance outlines the information that should be submitted to FDA, the timing of the submissions, a preferred format 28 for the submissions, and a preferred method for reporting to FDA.

“The DSCSA requires contact information to be submitted by wholesale distributors.”
FDA submission for Wholesale Distributors is a must.

What needs to be submitted:

The DSCSA requires contact information to be submitted by wholesale distributors. FDA considers contact information to include the email address and telephone number of the person who will interact with the FDA. In addition to the specific information required by DSCSA to be submitted to the Agency, FDA has identified additional information that will enhance efficiencies and improve accuracy in the management of the licensing and facility information submitted to the Agency. Therefore, FDA is requesting that certain additional information be submitted to FDA on a voluntary basis. This additional information will be useful to FDA in its enforcement of the Act and to stakeholders as they make decisions about their drug product distribution. Furthermore, FDA is requesting the same information from wholesale distributors and 3PLs. The ultimate goal is for the public database to serve as a single repository of licensing and facility information for wholesale drug distributors and 3PLs conducting business in the United States.

Where do you need to go to submit this information?

If you are a client of TrackTraceRx, we assist you in this submittal. If not please look at these links:
The actual form:

To register for the form:

When should you fill out this information?

Wholesale distributors: January 1, 2015–March 31, 2015

What about for newly registered company?

Wholesale distributor and 3PL facilities that are newly licensed after the dates noted above should initially report within 30 days of obtaining a State or Federal license.

When do I have to re-submit my information on an annual basis?

Wholesale distributors: January 1–March 31 annually

What else?

Reports of significant disciplinary actions should be submitted to FDA when a final action or ruling has been made by a State or Federal licensing authority.

Wholesale distributors: within 30 days of final action

A company should notify FDA if a facility goes out of business or decides to voluntarily withdraw a State or Federal license.

How do i submit this report?

FDA prefers the use of extensible markup language (XML) files in a standard Structured Product 268 Labeling (SPL)4 format.


Register and fill out the form here:

Follow our Step-by-Step guide here:

Share on social media: 

More from TrackTraceRx Blog

TrackTraceRX in the SETRM and 2020 Gaesi Annual seminar on implementation of the SNCM

Scheduled to be held in the month of September 2020, the seminar will have participants belonging to the academia, corporate sector, and different governments to strengthen Brazil’s intent to implement the drug regulations by May 2022. The Brazilian Health Regulatory Agency (ANVISA) is serious about implementing a comprehensive nationwide serialization solution so that communication between pharmaceutical supply chain stakeholders is transparent.

Read Story

Wholesaler Question: Am I to able break down my package and sell individual vials without Serial numbers?

We recently received this question from a wholesaler. Their business relied in purchasing serialized products, removing each single unit vials from the box and selling each individual vials to physicians. The problem is that each vial does not have a serial number. Can they do that? Let's analyze.

Read Story

How YOU can Prepare for Interoperable Technology to meet the DSCSA requirements

Drug supply chain trading partners, including manufacturers, wholesalers, distributors, pharmacies, and other pharmaceutical related businesses have been adapting to the changes outlined in the DSCSA regarding how trading partners handle the serialization and traceability of pharmaceutical products. As we’ve said farewell to phase I of the DSCSA, it’s time to look ahead to phase II, which includes a focus on interoperability for the industry.

Read Story

Never miss a minute.

Receive notifications of new Track & Trace articles.
We will never share your email address with third parties.